BioPharmSignal logoBioPharmSignal

Biotech News

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

Emergent BioSolutions (EBS)Emergent BioSolutionsCompany update

GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS, SAB BIO) to support the process development and manufacturing of SAB-142, SAB BIO’s lead program in clinical development

Related news

EBSEmergent BioSolutions2026-04-28 12:01 EST

Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States

EBSEmergent BioSolutions2026-05-28 20:01 EST

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

View all latest news

Emergent BioSolutions

Emergent BioSolutions is a biodefense and specialty products company focused on public-health preparedness, vaccines, and medical countermeasures. Its business is centered on government and specialty healthcare contracts.

Recent company news

EBSEmergent BioSolutions2026-05-28 20:01 EST

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

EBSEmergent BioSolutions2026-05-20 11:30 EST

Emergent BioSolutions to Participate in Upcoming Investor Conferences

EBSEmergent BioSolutions2026-05-18 12:59 EST

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

EBSEmergent BioSolutions2026-04-30 20:30 EST

Emergent BioSolutions Reports First Quarter 2026 Financial Results

EBSEmergent BioSolutions2026-04-30 11:55 EST

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

Stock data

Close
5.08 USD
Market cap
423.61M USD
Exchange
NYSE
Sector
Biopharma
Location
United States